Ginkgo Bioworks: Novo Deal and AI Data Drive Long-Term Potential

Ginkgo Bioworks reported third-quarter 2026 earnings on November 5, highlighting a strategic pivot toward selling autonomous laboratory hardware and cloud data services. The company aims to commercialize its automated biology platform, moving beyond traditional service-based revenue.

A key development was the announcement that pharmaceutical giant Novo Nordisk selected Ginkgo to build an autonomous lab at its new R&D site in Waltham, Massachusetts. This marks Ginkgo's first major pharma customer for its autonomous lab offering, which CEO Jason Kelly believes will signal to the industry that the technology is ready for prime time.

Financially, Ginkgo has been restructuring to reduce costs. The company ended the quarter with $285 million in cash and no bank debt, plus $86 million in restricted cash. Management noted that adjusted EBITDA improved due to cost cuts, while still investing in R&D for autonomous labs, AI, and robotics.

Additionally, Ginkgo sees growing demand from frontier AI labs that need physical laboratory data to train complex models. CEO Jason Kelly stated that as long as AI labs push the boundaries of their capabilities in physical areas, they will want to train on physical data, opening a new revenue stream for Ginkgo's automated data generation services.

The Novo Nordisk deal is a significant validation of Ginkgo's autonomous lab technology. Big pharma adoption creates high switching costs and recurring revenue potential, as these systems are deeply integrated into R&D workflows. This could lead to more partnerships and establish Ginkgo as a key player in lab automation.

The restructuring has stabilized Ginkgo's liquidity, giving the company more runway to execute its strategy. With no debt and a solid cash position, Ginkgo can continue investing in its platform without immediate financial pressure. Improved adjusted EBITDA indicates that cost cuts are paying off, though the company still needs to achieve sustainable profitability.

The demand from AI labs for physical data is a emerging opportunity. As AI models become more sophisticated, they require real-world experimental data, which Ginkgo can provide through its automated labs. This positions Ginkgo at the intersection of AI and biotech, potentially unlocking high-margin revenue streams.

However, the transition to a product-based model carries execution risks. Scaling hardware deployments and achieving recurring software revenue will take time. Investors should monitor adoption rates and the company's ability to reduce cash burn further while growing revenue.